Novavax reported Q4 2025 total revenue of 147139000 and net income of 17527000, compared to a net loss in the prior year period. Operating income turned positive to 14230000 as R&D and SG&A expenses declined materially year-over-year.
Total revenue increased to 147139000 from 88311000 year-over-year.
Net income was 17527000 compared to a net loss of 81030000 in Q4 2024.
R&D expenses declined to 75876000 from 104380000 year-over-year.
SG&A expenses decreased to 34122000 from 78342000 year-over-year.
For full year 2026, Novavax expects Adjusted Total Revenue between 230000000 and 270000000 and Non-GAAP Combined R&D and SG&A Expenses between 310000000 and 340000000.
Visualization of income flow from segment revenue to net income
Analyze how earnings announcements historically affect stock price performance